Iovance Biotherapeutics, Inc. Share Price Today: Live Updates & Key Insights

Iovance Biotherapeutics, Inc. share price today is $3.74, up -4.65%. The stock opened at $3.83 against the previous close of $3.87, with an intraday high of $3.95 and low of $3.61.

Iovance Biotherapeutics, Inc. Share Price Chart

Iovance Biotherapeutics, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Iovance Biotherapeutics, Inc. Share Price Performance

$3.74 -0.0465(-4.65%) IOVA at 23 Mar 2026 01:41 PM Biotechnology
Lowest Today 3.61
Highest Today 3.95
Today’s Open 3.83
Prev. Close 3.87
52 Week High 5.63
52 Week Low 1.64
Day’s Range: Low 3.61 High 3.95
52-Week Range: Low 1.64 High 5.63
1 day return -
1 Week return -8.64
1 month return +28.02
3 month return +33.33
6 month return +76.19
1 year return +2.2
3 year return -37.6
5 year return -88.58
10 year return -

Iovance Biotherapeutics, Inc. Institutional Holdings

Mhr Fund Management Llc 7.03

Vanguard Group Inc 6.60

BlackRock Inc 6.30

State Street Corp 3.23

Invenomic Capital Management, LP 2.90

State Street® SPDR® S&P® Biotech ETF 2.85

Vanguard Total Stock Mkt Idx Inv 2.72

Long Focus Capital Management, LLC 2.09

Geode Capital Management, LLC 1.94

Palo Alto Investors, LLC 1.85

iShares Russell 2000 ETF 1.81

Millennium Management LLC 1.60

The Goldman Sachs Group Inc 1.60

Bank of America Corp 1.52

Morgan Stanley - Brokerage Accounts 1.35

Invenomic Institutional 1.22

Susquehanna International Group, LLP 1.20

Two Sigma Investments LLC 1.07

HRT FINANCIAL LLC 1.06

Vanguard Small Cap Index 0.98

D. E. Shaw & Co LP 0.93

Vanguard Institutional Extnd Mkt Idx Tr 0.88

Jane Street Group LLC 0.87

Citadel Advisors Llc 0.76

Fidelity Small Cap Index 0.73

Two Sigma Advisers, LLC 0.73

Principal Financial Group Inc 0.73

iShares Russell 2000 Value ETF 0.64

Vanguard Small Cap Value Index Inv 0.63

iShares Biotechnology ETF 0.60

State St Russell Sm/Mid Cp® Indx SL Cl I 0.43

Fidelity Extended Market Index 0.43

Schwab US Small-Cap ETF™ 0.39

Rhenman Healthcare Equity L/S RC2 SEK 0.39

Vanguard Russell 2000 ETF 0.36

Stt Strt®SPDR®S&PKenshoNwEcosComposETF 0.32

C WorldWide Healthcare Select 1A 0.31

BlackRock Advantage Small Cap Core Instl 0.27

JPM Thematics Genetic Thrps C2 dist USD 0.26

Invesco RAFI US 1500 Small-Mid ETF 0.26

Iovance Biotherapeutics, Inc. Market Status

Strong Buy: 5

Buy: 3

Hold: 4

Sell: 0

Strong Sell: 0

Iovance Biotherapeutics, Inc. Fundamentals

Market Cap 1520.14 M

PB Ratio 2.1819

PE Ratio 0.0

Enterprise Value 1276.72 M

Total Assets 913.17 M

Volume 23502040

Iovance Biotherapeutics, Inc. Company Financials

Annual Revenue FY25:263502000 263.5M, FY23:707000 0.7M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY25:256216000 256.2M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY25:-390978000 -391.0M, FY23:-432977000 -433.0M, FY22:-389923000 -389.9M, FY21:-327821000 -327.8M, FY20:-257225000 -257.2M

Quarterly Revenue Q4/2025:86771000 86.8M, Q3/2025:67455000 67.5M, Q2/2025:59952000 60.0M, Q1/2025:49324000 49.3M, Q3/2024:58554000 58.6M

Quarterly Profit Q4/2025:187298000 187.3M, Q3/2025:66047000 66.0M, Q2/2025:3288000 3.3M, Q1/2025:-417000 -0.4M, Q3/2024:18731000 18.7M

Quarterly Net worth Q4/2025:-71904000 -71.9M, Q3/2025:-91253000 -91.3M, Q2/2025:-111658000 -111.7M, Q1/2025:-116163000 -116.2M, Q3/2024:-83541000 -83.5M

About Iovance Biotherapeutics, Inc. & investment objective

Company Information Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Organisation Biotechnology

Employees 975

Industry Biotechnology

CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Iovance Biotherapeutics, Inc. FAQs

What is the share price of Iovance Biotherapeutics, Inc. today?

The current share price of Iovance Biotherapeutics, Inc. is $3.74.

Can I buy Iovance Biotherapeutics, Inc. shares in India?

Yes, Indian investors can buy Iovance Biotherapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Iovance Biotherapeutics, Inc. shares in India?

You can easily invest in Iovance Biotherapeutics, Inc. shares from India by:

Can I buy fractional shares of Iovance Biotherapeutics, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Iovance Biotherapeutics, Inc.?

Iovance Biotherapeutics, Inc. has a market cap of $1520.14 M.

In which sector does Iovance Biotherapeutics, Inc. belong?

Iovance Biotherapeutics, Inc. operates in the Biotechnology sector.

What documents are required to invest in Iovance Biotherapeutics, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Iovance Biotherapeutics, Inc.?

The PE ratio of Iovance Biotherapeutics, Inc. is N/A and the PB ratio is 2.18.